Literature DB >> 12078875

Osteosarcoma occurring in osteogenesis imperfecta tarda.

S Maiya1, R J Grimer, R Ramaswamy, N S Deshmukh.   

Abstract

The combination of osteogenesis imperfecta (OI) and osteosarcoma is rare, as reflected by the fact that there are only eight proven cases in the published English literature. We present here another case, one that was treated by modern oncological techniques and major limb salvage surgery in the form of distal femur endoprosthesis initially and later a total femur replacement. The patient is the only one of the series to have had major limb salvage and is the only--and longest--surviving patient (more than 6 years), thus disproving the probability that this combination of disorders is particularly lethal. We present the case history, review the literature, and look at the cases presented in the past. We contend that adequate awareness, early diagnosis, and prompt oncological management results in better prognosis for osteosarcoma occurring in OI.

Entities:  

Mesh:

Year:  2002        PMID: 12078875      PMCID: PMC3620876          DOI: 10.1007/s00264-001-0323-3

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  3 in total

1.  Hyperplastic callus formation in osteogenesis imperfecta type V mimicking osteosarcoma: 4-year follow-up with resolution.

Authors:  R L V Vieira; D T Amaral; Filho R Jesus-Garcia; G Saraiva; A R C Fernandes; D Resnick
Journal:  Skeletal Radiol       Date:  2005-11-25       Impact factor: 2.199

Review 2.  Osteosarcoma occurring in osteogenesis imperfecta.

Authors:  Shu Takahashi; Kyoji Okada; Hiroyuki Nagasawa; Yoichi Shimada; Hitoshi Sakamoto; Eiji Itoi
Journal:  Virchows Arch       Date:  2004-05       Impact factor: 4.064

3.  Expanding the phenotypic spectrum of osteogenesis imperfecta type V including heterotopic ossification of muscle origins and attachments.

Authors:  Pantelis Clewemar; Nils P Hailer; Yasmin Hailer; Joakim Klar; Andreas Kindmark; Östen Ljunggren; Eva-Lena Stattin
Journal:  Mol Genet Genomic Med       Date:  2019-05-16       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.